Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.89 |
| ▸ | BTK | Q06187 | 6/20 | 0.80 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.67 |
| ▸ | ITK | Q08881 | 1/20 | 0.62 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.61 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.61 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12519461 | 0.94 | EGFR (1.00) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL29722500 | 0.90 | EGFR (1.00) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL12519518 | 0.90 | EGFR (1.00) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL12519451 | 0.89 | EGFR (1.00) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL29722381 | 0.89 | EGFR (1.00) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL21443504 | 0.89 | EGFR (0.89) | EGFRBTKMAPK3ITKPTK2 | |
| SCHEMBL13185131 | 0.87 | EGFR (0.83) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL12518491 | 0.86 | EGFR (0.85) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL12518480 | 0.83 | EGFR (0.86) | EGFRBTKMAPK3ITKERBB2 | |
| SCHEMBL12519783 | 0.82 | EGFR (0.85) | EGFRBTKITKERBB2ERBB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | CELGENE CAR LLC (BM) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351168-B1 | 2,4-disubstituted pyrimidines useful as kinase inhibitors | DCK, CDK2, DTYMK | EGFR 460/4885BTK 261/4885MAPK3 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.